Since KRAS, TRP53, and NOTCH1 gene mutations play a critical role in mCRC in humans, the human-CMS4 like CRC tumor characteristics in KPN makes it an interesting model to evaluate therapy driven anti-tumor immune response. This evidence concerns the gene KRAS and neoplasm.